Education
About Us
Working with TipRanks
Follow Us
Amgen (AMGN)
NASDAQ:AMGN
AMGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$253.30 - $346.85
Previous CloseN/A
Volume614.18K
Average Volume (3M)3.15M
Market Cap
$169.78B
Enterprise Value$190.17B
Total Cash (Recent Filing)$11.97B
Total Debt (Recent Filing)$60.10B
Price to Earnings (P/E)41.8
Beta0.38
Next Earnings
Apr 23, 2025EPS Estimate
4.29Next Dividend Ex-Date
May 16, 2025Dividend Yield2.89%
Share Statistics
EPS (TTM)7.55
Shares Outstanding537,204,960
10 Day Avg. Volume3,351,938
30 Day Avg. Volume3,150,826
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.08
Price to Cash Flow (P/CF)8.90
P/FCF Ratio7.90
Enterprise Value/Market Cap1.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.25
Enterprise Value/Ebitda14.24
Forecast
1Y Price Target
$329.92Price Target Upside4.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAMGN provided surprisingly positive topline data from the Ph3 ROCKET-IGNITE trial for rocatinlimab in the treatment of atopic dermatitis.
Market PositionAMGN could differentiate with its Q4W dosing, which is less frequent compared to competitors like dupi's Q2W dosing, making it appealing for patients who are dupi refractory.
Bears Say
Efficacy And SafetyRocatinlimab's efficacy and safety profile in atopic dermatitis is weak compared to approved agents, making it unlikely to challenge market positioning.
Safety ConcernsSafety concerns such as 10% of patients experiencing fever/chills could limit AMGN's competitiveness against other treatments.
---
Ownership Overview
0.22% Insiders
21.69% Mutual Funds
18.85% Other Institutional Investors
31.16% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AMGN FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was $253.30 and its highest was $346.85 in the past 12 months.
What is Amgen’s market cap?
Amgen’s market cap is $169.78B.
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Apr 23, 2025 which is in 29 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Feb 04, 2025. The company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.091 by $0.219.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of $2.38 which represents an annual dividend yield of 2.89%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is 4.29.
How many shares outstanding does Amgen have?
Amgen has 537,204,960 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of $5.31 in its last earnings report, beating expectations of $5.091. Following the earnings report the stock price went up 6.502%.
Which hedge fund is a major shareholder of Amgen?
Currently, no hedge funds are holding shares in AMGN
---
Amgen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$329.92 (4.94% Upside)
$329.92 (4.94% Upside)
Blogger Sentiment
Bullish
AMGN Sentiment 87%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 969.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $20.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.59%
12-Months-Change
Fundamentals
Return on Equity
67.55%
Trailing 12-Months
Asset Growth
-5.47%
Trailing 12-Months
Company Description
Amgen
Amgen Inc. is a leading biotechnology company dedicated to discovering, developing, manufacturing, and delivering innovative human therapeutics. Headquartered in Thousand Oaks, California, Amgen focuses on applying advanced science to address serious illnesses in areas such as oncology, hematology, cardiovascular disease, neuroscience, nephrology, and inflammation. The company's core products include biologic therapies and small-molecule drugs that provide significant benefits to patients worldwide.
---
AMGN Company Deck
---
AMGN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance in 2024 with significant growth in product sales, particularly in oncology and biosimilars. The successful integration of Horizon and robust financial results further reinforce Amgen's position for continued growth. However, challenges such as the upcoming patent expiration for denosumab and expected price declines pose potential risks.Read More>---
AMGN Revenue Breakdown
13.09% Prolia
9.92% Enbrel
6.66% XGEVA
6.65% Repatha
63.69% Other
---
AMGN Stock 12 Month Forecast
Average Price Target
$329.92
▲(4.94% Upside)
Technical Analysis
Best Analysts Covering AMGN
1 Year
1 Year Success Rate
28/36 ratings generated profit
1 Year Average Return
+14.08%
reiterated a buy rating 15 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +14.08% per trade.
---